Enhanced antitumor efficacy by Paclitaxel-loaded Pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 75, Issue 3, 2010, Pages 341-353

  Zhang, Wei ^a   Shi, Yuan ^b   Chen, Yanzuo ^a   Yu, Shuangyin ^a   Hao, Junguo ^a   Luo, Jieqi ^a   Sha, Xianyi ^a   Fang, Xiaoling ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Hengrui Pharmaceutical Co Ltd   (China)

Author keywords

A 549; Multidrug resistance; Paclitaxel; Pluronic; Polymeric micelles

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOSPORIN A; GENEXOL PM; PACLITAXEL; PLURONIC F127; PLURONIC P123; POLOXAMER; POLYMER; RHODAMINE B; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MICELLE; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIDRUG RESISTANCE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SINGLE DRUG DOSE; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MICELLES; PACLITAXEL; POLOXALENE;

EID: 77954535848     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.04.017     Document Type: Article

References (70)

1. Jemal A., Thun M.J., Ries L.A., Howe H.L., Weir H.K., Center M.M. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J. Natl. Cancer Inst. 2008, 100:1672-1694.
2. Trussardi A., Poitevin G., Gorisse M.C., Faroux M.J., Bobichon H., Delvincourt C., Jardillier J.C. Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells. Int. J. Oncol. 1998, 13:543-548.
3. Berger W., Setinek U., Hollaus P., Zidek T., Steiner E., Elbling L., Cantonati H., Attems J., Gsur A., Micksche M. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J. Cancer. Res. Clin. Oncol. 2005, 131:355-363.
4. Meschini S., Marra M., Calcabrini A., Monti E., Gariboldi M., Dolfini E., Arancia G. Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells. Toxicol. in Vitro 2002, 16:389-398.
5. Kitazono M., Sumizawa T., Takebayashi Y.J., Chen Z.S., Furukawa T., Nagayama S.C., Tani A., Takao S., Aikou T., Akiyama S. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J. Natl. Cancer Inst. 1999, 91:1647-1653.
6. Kang H.K., Lee E., Pyo H., Lim S.J. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol. Cancer Ther. 2005, 4:1358-1363.
7. Imai Y., Nakane M., Kage K., Tsukahara S., Ishikawa E., Tsuruo T., Miki Y., Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 2002, 1:611-616.
8. Hira A., Watanabe H., Maeda Y., Yokoo K., Sanematsu E., Fujii J., Sasaki J., Hamada A., Saito H. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells. Biochem. Pharmacol. 2008, 75:973-980.
9. Lee E., Lim S.J. The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines. Arch. Pharm. Res. 2006, 29:1018-1023.
10. Lee E.S., Gao Z.G., Kim D., Park K., Kwon I.C., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance. J. Control. Release 2008, 129:228-236.
11. Spencer C.M., Faulds D. Paclitaxel - a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994, 48:794-847.
12. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulation. Int. J. Pharm. 2002, 235:179-192.
13. Weiss R.B., Donehower R.C., Wiernik P.H. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 1990, 8:1263-1268.
14. Michael J.H., Patrick S.S., Neil D. Protein nanoparticles as drug carrier in clinical medicine. Adv. Drug Deliv. Rev. 2008, 60:876-885.
15. Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., Rha S.Y., Lee M.Y., Ro J. Multicenter phaseIItrial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008, 108:241-250.
16. Devalapally H., Duan Z., Seiden M.V., Amiji M.M. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin. Cancer Res. 2008, 14:3193-3203.
17. Bradley G., Juranka P.F., Ling V. Mechanism of multidrug resistance. Biochem. Biophys. Acta. 1988, 948:87-128.
18. Harris A.L., Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta. Oncol. 1992, 31:205-213.
19. Rahman A., Husain S.R., Siddiqui J., Verma M., Agresit M., Center M., Safa A.R., Glazer R.I. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J. Natl. Cancer Inst. 1992, 84:1909-1915.
20. Booser D.J., Esteva F.J., Rivera E., Valero V., Esparza G.L., Priebe W., Hortobagyi G.N. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer. Chemother. Pharmacol. 2002, 50:6-8.
21. Garcion E., Lamprecht A., Heurtault B., Paillard A., Aubert-Pouessel A., Denizot B., Menei P., Benoit J.P. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer. Ther. 2006, 5:1710-1722.
22. Vauthier C., Dubernet C., Chauvierre C., Brigger I., Couvreur P. Drug delivery to resistant tumors: the potential of poly (alkyl cyanoacrylate) nanoparticles. J. Control. Release 2003, 93:151-160.
23. Koziara J.M., Whisman T.R., Tseng M.T., Mumper R.J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 2006, 112:312-319.
24. Minko T., Kopeckova P., Pozharov V., Kopeck J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 1998, 54:223-233.
25. Minko T., Kopeckova P., Kopeck J. Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J. Control. Release 2001, 71:227-237.
26. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 2002, 54:759-779.
27. Batrakova E.V., Kelly D.L., Li S., Li Y., Yang Z., Xiao L., Alakhova D.Y., Sherman S., Kabanov A.V., Alakhov V.Y. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85. Mol. Pharm. 2006, 3:113-123.
28. Jabr-Milance L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008, 34:592-602.
29. Danson S., Ferry D., Alakhov V.Y., Margison J., Kerr D., Jowle D., Brampton M., Halbert G., Ranson M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 2004, 90:2085-2091.
30. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., Shirao K., Okusaka T., Ueno H., Ikeda M., Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Brit. J. Cancer 2004, 91:1775-1781.
31. Mizumura Y., Matsumura Y., Yokoyama M., Okano T., Kawaguchi T., Moriyasu F., Kakizoe T. Incorporation of the anticancer agent KRN5500 into polymeric micelles diminishes the pulmonary toxicity. Jpn. J. Cancer Res. 2002, 93:1237-1243.
32. Matsumura Y. Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles. J. Drug Target 2007, 15:507-517.
33. A. Armstrong, J. Brewer, C. Newman, V. Alakhov, G. Pietrzynski, S. Campbell, P. Corrie, M. Ranson, J.W. Valle, SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: a phaseIIwindow study. ASCO Annual Meeting Proceedings Part I, J. Clin. Oncol. 24 (2006) 4080.
34. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release 2008, 130:98-106.
35. Zhang W., Hao J.G., Shi Y., Li Y.J., Wu J., Sha X.Y., Fang X.L. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int. J. Pharm. 2009, 376:176-185.
36. Lu H.F., Lim W.S., Wang J., Tang Z.Q., Zhang P.C., Leong K.W., Chia S.M., Yu H., Mao H.Q. Galactosylated PVDF membrane promotes hepatocyte attachment and functional maintenance. Biomaterials 2003, 24:4893-4903.
37. Patil Y.B., Toti U.S., Wong W., Khdair A., Ma L., Panyam J. Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials 2009, 30:859-866.
38. Hong M.H., Zhu S.J., Jiang Y.Y., Tang G.T., Pei Y.Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated ninosomes modified with transferrin. J. Control. Release 2009, 133:96-102.
39. Yuan H., Miao J., Du Y.Z., You J., Hu F.Q., Zeng S. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int. J. Pharm. 2008, 348:137-145.
40. Ham A.S., Cost M.R., Sassi A.B., Dezzutti C.S., Rohan L.C. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 2009, 26:502-511.
41. Batarkova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of Pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol Exp. Ther. 2001, 299:483-493.
42. Zastre J.A., Jackson J.K., Wong W., Burt H.M. P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity. Mol. Pharm. 2008, 5:643-653.
43. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br. J. Cancer 2001, 85:1987-1997.
44. Shaik N., Giri N., Elmquist W.F. Investigation of the micellar effect of Pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. J. Pharm. Sci. 2009, 98:4170-4190.
45. Petit P.X., Lecoeur H., Zorn E., Dauguet C., Mignotte B., Gougeon M.L. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J. Cell Biol. 1995, 130:157-167.
46. Petit P.X., Zamzami N., Vayssiere J.L., Mignotte B., Kroemer G., Castedo M. Implication of mitochondria in apoptosis. Mol. Cell. Biochem. 1997, 174:185-188.
47. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
48. Duke R.C., Ojcius D.M., Young J.D. Cell suicide in health and disease. Sci. Am. 1996, 275:80-87.
49. Lee H.C., Wei Y.H. Mitochondrial role in life and death of the cell. J. Biomed. Sci. 2000, 7:2-15.
50. Rapoport N., Pitt W.G., Sun H., Nelson J.L. Drug delivery in polymeric micelles: from in vitro to in vivo. J. Control. Release 2003, 91:85-95.
51. Melik-Nubarov N.S., Pomaz O.O., Dorodnych T.Y., Badum G.A., Ksenofontov A.L., Schemchukova O.B., Arzhakov S.A. Interaction of tumor and normal blood cells with ethylene oxide and propylene oxide block copolymers. FEBS Lett. 1999, 446:194-198.
52. Liebmann J., Cook J.A., Mitchell J.B. Cremophor EL solvent for paclitaxel and toxicity. Lancet. 1993, 342:1428.
53. Liebmann J., Cook J.A., Lipschultz C., Teague D., Fisher J., Mitchell J.B. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother. Pharmacol. 1994, 33:331-339.
54. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc. Natl. Acad. Sci. USA 1993, 90:9552-9556.
55. Batrakova E.V., Li S., Alakhov V.Y., Miller D.W., Kabanov A.V. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 2003, 304:845-854.
56. Minko T., Batrakova E.V., Li S., Li Y.L., Pakunlu R.I., Alakhov V.Y., Kabanov A.V. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J. Control. Release 2005, 105:269-278.
57. Sharma K., Zhang L., Li S., Kelly D.L., Alakhov V.Y., Batrakova E.V., Kabanov A.V. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J. Control. Release 2008, 131:220-227.
58. Guo D.D., Moon H.S., Arote R., Seo J.H., Quan J.S., Choi Y.J., Cho C.S. Enhanced anticancer effect of conjugated linoleic acid by conjugation with Pluronic F127 on MCF-7 breast cancer cells. Cancer Lett. 2007, 254:244-254.
59. Guo D.D., Xu C.X., Quan J.S., Song C.K., Jin H., Kim D.D., Choi Y.J., Cho M.H., Cho C.S. Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivo. Biomaterials 2009, 30:4777-4785.
60. Ahmed F., Pakunlu R.I., Brannan A., Bates F., Minko T., Discher D.E. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors by inducing apoptosis in proportion to accumulated drug. J. Control. Release 2006, 116:150-158.
61. Ng S.S.W., Tsao M.S., Chow S., Hedley D.W. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 2000, 60:5451-5455.
62. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37:1590-1598.
63. Sparreboom, van Zuylen L., Brouwer E., Loos W.J., de Bruijn P., Gelderblom H., Pillay M., Nooter K., Stoter G., Verweij J. Cremophor EL-meidated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999, 59:1454-1457.
64. Han L.M., Guo J., Zhang L.J., Wang Q.S., Fang X.L. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel. Acta. Pharmacol. Sin. 2006, 27:747-753.
65. Wang Y.Z., Li Y.J., Zhang L.J., Fang X.L. Pharmacokinetics and biodistribution of paclitaxel-loaded Pluronic P105 polymeric micelles. Arch. Pharm. Res. 2008, 31:530-538.
66. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release 2002, 82:189-212.
67. Ueda K., Kawaguchi Y., Iwakawa S. Effect of oxyethylene numbers on the pharmacokinetics of menatetrenone incorporated in oil-in-water lipid emulsions prepared with polyoxyethylene-polyoxypropylene block copolymers and soybean oil in rats. Biol. Pharm. Bull. 2008, 31:2283-2287.
68. Batrakova E.V., Li S., Li Y.L., Alakhov V.Y., Elmquist W.F., Kabanov A.V. Distribution kinetics of a micelle-forming block copolymer Pluronic P85. J. Control. Release 2004, 100:389-397.
69. Grindel M., Jaworski T., Piraner O., Emanuele R.M., Balasubramanian M. Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J. Pharm. Sci. 2002, 91:1936-1947.
70. Chang L.C., Chang Y.Y., Gau C.S. Interfacial properties of Pluronics and the interactions between Pluronics and cholesterol/DPPC mixed monolayers. J. Colloid Interface Sci. 2008, 322:263-273.